ShareValue scores for THEMISMED.NSE: Valuation 60, Quality 34, Growth 25, Health 45.

Themis Medicare Limited logo

THEMISMED.NSE
NSE

Themis Medicare Limited

₹114.00(-1.77%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 16%
Valuation
60
Fair Value
Price vs Value
Quality
34
Weak
Business Strength
Growth
25
Weak
Revenue & Earnings
Health
45
Moderate
Financial Stability
Momentum
64
Bullish
Price Trend

Company Details

About

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, hematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasodilator, vasopressors, and vitamins. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is based in Mumbai, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026